Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro

Genetics and Molecular Research

Volumn 14, Issue 1, 2015, Pages 2450-2460

  Tang, Y J ^a   Sun, Z L ^a   Wu, W G ^a   Xing, J ^a   He, Y F ^a   Xin, D M ^a   Han, P ^a  

^a HEBEI UNITED UNIVERSITY   (China)

Author keywords

Cisplatin; Inhibitory effect; Ovarian cancer; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; CISPLATIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN; TYRPHOSTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MTT ASSAY; OVARY CANCER; PROTEIN PHOSPHORYLATION; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; OVARIAN NEOPLASMS; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; FEMALE; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PYRIDINES; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84926304367     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.March.30.3     Document Type: Article

References (34)

1. Boreddy SR, Sahu RP and Srivastava SK (2011). Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One 6: e25799.
2. Buettner R, Mora LB and Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8: 945-954.
3. Chen X, Du Y, Nan J, Zhang X, et al. (2013). Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One 8: e63697.
4. Corney DC, Hwang CI, Matoso A, Vogt M, et al. (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16: 1119-1128.
5. Daniel JM, Dutzmann J, Bielenberg W, Widmer-Teske R, et al. (2012). Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res. Cardiol. 107: 261.
6. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, et al. (2013). Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 73: 2480-2492.
7. Du J, Cheng B, Zhu X and Ling C (2011). Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects. J. Immunol. 187: 942-950.
8. Duan Z, Foster R, Bell DA, Mahoney J, et al. (2006). Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 12: 5055-5063.
9. Duan Z, Ames RY, Ryan M, Hornicek FJ, et al. (2009). CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother. Pharmacol. 63: 681-689.
10. Ferrajoli A, Faderl S, Van Q, Koch P, et al. (2007). WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 67: 11291-11299.
11. Fossey SL, Liao AT, McCleese JK, Bear MD, et al. (2009). Characterization of STAT3 activation and expression in canineand human osteosarcoma. BMC Cancer 9: 81.
12. Hatiboglu MA, Kong LY, Wei J, Wang Y, et al. (2012). The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int. J. Cancer 131: 8-17.
13. Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, et al. (2007). A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int. J. Gynecol. Cancer 17: 561-570.
14. Horiguchi A, Asano T, Kuroda K, Sato A, et al. (2010). STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer 102: 1592-1599.
15. Ihle JN (1995). The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol. 60: 1-35.
16. Iwamaru A, Szymanski S, Iwado E, Aoki H, et al. (2007). A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435-2444.
17. Johnston PA and Grandis JR (2011). STAT3 signaling: anticancer strategies and challenges. Mol. Interv. 11: 18-26.
18. Kaneko N, Kita A, Yamanaka K and Mori M (2013). Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. Leuk. Res. 37: 1156-1161.
19. Kim M, Yoon S, Lee S, Ha SA, et al. (2012). Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. PLoS One 7: e35100.
20. Leeman RJ, Lui VW and Grandis JR (2006). STAT3 as a therapeutic target in head and neck cancer. Expert Opin. Biol. Ther. 6: 231-241.
21. Liu K, Jiang M, Lu Y, Chen H, et al. (2013). Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 12: 304-315.
22. Messina JL, Yu H, Riker AI, Munster PN, et al. (2008). Activated stat-3 in melanoma. Cancer Control 15: 196-201.
23. Ozols RF, Bookman MA, du Bois A, Pfisterer J, et al. (2006). Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol. Oncol. 103: 1-6.
24. Parker RJ, Eastman A, Bostick-Bruton F and Reed E (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87: 772-777.
25. Quintas-Cardama A, Kantarjian H, Cortes J and Verstovsek S (2011). Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov. 10: 127-140.
26. Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, et al. (2006). The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107: 2730-2740.
27. Touboul C, Lis R, Al Farsi H, Raynaud CM, et al. (2013). Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J. Transl. Med. 11: 28.
28. Vermeij J, Teugels E, Bourgain C, Xiangming J, et al. (2008). Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 8: 3.
29. Wei J, Wu A, Kong LY, Wang Y, et al. (2011). Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6: e16195.
30. Xu YZ, Xi QH, Ge WL and Zhang XQ (2013). Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 14: 1057-1060.
31. Yan N, Zhang S, Yang Y, Cheng L, et al. (2012). Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis. Cancer Sci. 103: 1631-1639.
32. Yang F, Zhang W, Li D and Zhan Q (2013). Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway. J. Biol. Chem. 288: 6552-6560.
33. Zhang Q, Gong R, Qu J, Zhou Y, et al. (2012). Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. J. Virol. 86: 1544-1554.
34. Zhao SH, Zhao F, Zheng JY, Gao LF, et al. (2011). Knockdown of stat3 expression by RNAi inhibits in vitro growth of human ovarian cancer. Radiol. Oncol. 45: 196-203.